Part 1 Cancers: genetic insights, molecular mechanisms, and emerging therapies<br>Chapter 1: Breast cancer and new methods for treatment<br>Chapter 2: The role of genetic markers P53, BRCA1, and BRCA2 in breast cancer risk assessment in women<br>Chapter 3: MicroRNAs as key regulators of hormone dependent pathways in breast cancer<br>Part 2 Lung and prostate cancer: genetic abnormalities and biomarkers<br>Chapter 4: Genetic abnormalities of the EGFR pathway in the Middle East and North African patients with non-small cell lung cancer<br>Chapter 5: MicroRNAs: advances in biomarkers, diagnostics, and therapeutic strategies in prostate cancer<br>Part 3 HPV and cervical cancer: screening, prevention, and molecular mechanisms<br>Chapter 6: Human papillomavirus infections in cervical cells for cervical cancer screening<br>Chapter 7: MicroRNA and human herpesvirus 8 oncovirus in prostate cancer<br>Part 4 Vitamin D and immune modulation in cancer<br>Chapter 8: Prostate cancer antigen 3 as a diagnostic, prognostic, and therapeutic biomarker in prostate cancer<br>Chapter 9: Interaction of the vitamin D in cancer development and progression<br>Part 5 Emerging therapies and biomarkers in cancer<br>Chapter 10: Study of the role of microRNAs in epstein barr virus induced prostate carcinogenesis<br>Chapter 11: Addressing the burden of human papillomavirus-related cancers in North Africa: epidemiology, sociocultural barriers and prevention strategies<br>Part 6 Management of the COVID-19 pandemic: lessons learned, surveillance, and respiratory biomarkers in SARS-CoV-2 pathogenesis<br>Chapter 12: Management of the COVID-19 pandemic in Skhirate-Temara, Morocco: lessons in preparedness, surveillance, and rapid response<br>Chapter 13: Respiratory biomarkers in the pathogenesis of SARS-CoV-2<br>Part 7 Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and therapeutic implications in cancer<br>Chapter 14: Oncoviruses and cancer biomarkers: current and future perspectives<br>Chapter 15: MicroRNAs in cancer development: biomarkers, functions and therapy<br>Chapter 16: Viral miRNA’s: unlocking new frontiers in virus-induced cancers<br>Part 8 Genetic and molecular basis of cancer<br>Chapter 17: Molecular alterations involved in lung cancer<br>Chapter 18: Oncogenic BRAF in prostate cancer: exosomes and miRNA status and implications for targeted therapy<br>Chapter 19: Targeted therapy in prostate and bladder cancer—role of BRAF and RAS mutations<br>Chapter 20: In-depth analysis of tumor markers in leukemia<br>Part 9 Molecular mechanisms and therapeutic implications in cancer<br>Chapter 21: Nasopharyngeal cancer associated with epstein barr virus<br>Chapter 22: Molecular mechanisms of cervical cancer<br>Part 10 Economic and market analysis in cancer research<br>Chapter 23: Critical analysis of the cost savings generated by biomarkers and oncoviruses in healthcare<br>Chapter 24: Market analysis of exosome technologies for the diagnosis of genitourinary cancers<br>Part 11 Phage therapy and immune modulation<br>Chapter 25: Phagotherapy: The discreet power of our immune cells<br>Part 12 Emerging therapies and biomarkers in cancer<br>Chapter 26: Mechanism of resistance to platinum salt-based chemotherapy<br>Chapter 27: Marine algae as a source of bioactive compounds: unlocking anticancer potential<br>Chapter 28: Cervical cancer: new treatment approaches using microRNA<br>Chapter 29: Therapeutic potential of the intratumoral microbiota in tumors<br>Chapter 30: Molecular biomarkers in bladder cancer: identification and clinical relevance<br>Chapter 31: Emerging biomarker applications for precision targeting in bladder cancer therapy<br>Chapter 32: Fusion gene and cancer<br>Chapter 33: Immunotherapy biomarkers in melanoma: fromprogrammed death-ligand 1 expression to tumor mutational burden<br>Chapter 34: The role of vitamin D supplementation in cancer treatment<br>Chapter 35: The role of vitamin D in modulating immune responses against oncoviruses human papillomavirus, Epstein–Barr virus, and human herpesvirus-8<br>Part 13 Epigenetics and DNA methylation in cancer<br>Chapter 36: Post-transcriptional epigenetic marks: DNA and microRNA methylation<br>Chapter 37: Epigenetic mechanism induced by human herpesvirus 8 in prostate cancer<br>Chapter 38: Role of methylation DNA in cell regulation<br>Chapter 39: DNA methylation biomarkers in colorectal cancer<br>Part 14 Oncoviruses and viral-associated cancers<br>Chapter 40: Deciphering the molecular tapestry: extracellular vesicles as pioneering biomarker reservoirs for precision therapy in urogenital cancers<br>Chapter 41: Retroviruses as biomarkers in prostate carcinoma<br>Chapter 42: The role of breast cancer gene 1 and breast cancer gene 2 in determining breast cancer therapy<br>Chapter 43: The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosis<br>Chapter 44: Human papillomavirus as the main cause of cervical cancer: diagnosis, treatment, and prevention<br>Chapter 45: Oncogenic role of proline-rich protein 11 in breast and gynecologic cancers: mechanisms, signaling pathways, and therapeutic implications<br>Chapter 46: MicroRNAs as biomarkers in gynecological-mammary cancers<br>Chapter 47: Proline-rich protein 11 as a diagnosis and prognosis biomarker in breast and cervical cancers<br>Chapter 48: Recent advances in therapy and biomarkers: triple negative breast cancer<br>Chapter 49: Recent advances in exosome-based therapies for prostate cancer: targeting oncoviral and epigenetic pathways<br>Chapter 50: Exosomes as carriers of viral and host biomarkers in virus-associated gynecological cancers
